5-Amino-1MQ vs Humanin.

5-Amino-1MQ (5-amino-1-methylquinolinium) is a small-molecule, substrate-site inhibitor of the enzyme nicotinamide N-methyltransferase (NNMT). Despite being grouped with "peptides" in the research-chemical marketplace, it is not a peptide at all but a methylquinolinium heterocyclic salt that emerged from academic medicinal-chemistry work at the University of Texas aimed at producing membrane-permeable NNMT inhibitors. It is an investigational research compound, not an approved drug.

Humanin is a 24-amino-acid mitochondrial-derived peptide (MDP), one of the first members of a class of small peptides encoded by short open reading frames within the mitochondrial genome rather than the nuclear genome. Its coding sequence sits inside the mitochondrial 16S ribosomal RNA region (MT-RNR2), and a near-identical nuclear-encoded form also exists. It was discovered in 2001 by Hashimoto and colleagues in Ikuo Nishimoto's lab at Keio University during a cDNA screen for factors that protected neurons from Alzheimer's-disease-related insults, and it is studied primarily as a cytoprotective and metabolic signaling peptide.

NNMT is a cytosolic enzyme that transfers a methyl group from S-adenosylmethionine (SAM) to nicotinamide, generating 1-methylnicotinamide (1-MNA) and S-adenosylhomocysteine (SAH). Because nicotinamide is the precursor for NAD+ salvage, high NNMT activity in adipose tissue is thought to drain nicotinamide away from NAD+ synthesis and consume SAM. By occupying the nicotinamide substrate site, 5-Amino-1MQ lowers cellular 1-MNA and is proposed to spare nicotinamide for NAD+ regeneration and free up SAM-cycle methylation capacity. The downstream hypothesis (elevated NAD+ activating sirtuins/AMPK to favor energy expenditure over lipid storage) is mechanistically plausible but is largely inferred from cell and rodent work rather than directly demonstrated in humans.

Humanin acts both intracellularly and as a secreted, receptor-mediated factor. Intracellularly it binds and antagonizes the pro-apoptotic Bcl-2-family proteins BAX, tBID and BimEL, blocking their translocation to mitochondria and suppressing apoptosis. Extracellularly it signals through a tripartite cytokine-like receptor complex (CNTF receptor / WSX-1 / gp130) that activates STAT3, and also engages formyl-peptide receptors (FPRL1/FPR2). It modulates insulin/IGF-1 signaling, interacting with IGFBP-3 and enhancing AKT phosphorylation, and acts centrally in the hypothalamus as an insulin sensitizer; the engineered S14G analog (HNG) is far more potent than the native peptide in preclinical assays.

The core evidence is preclinical. Neelakantan et al. (Biochemical Pharmacology, 2018) reported that methylquinolinium NNMT inhibitors including 5-Amino-1MQ were membrane-permeable, relatively selective, lowered intracellular 1-MNA, and reduced lipogenesis in 3T3-L1 adipocytes; in diet-induced obese mice on a high-fat diet, systemic NNMT-inhibitor treatment significantly reduced body weight, white adipose mass, and adipocyte size and lowered plasma total cholesterol without changing food intake or producing observable adverse effects. Supporting context comes from Ehebauer et al. (Life Sciences, 2020) on glucose-dependent NNMT regulation in adipocytes, and Dimet-Wiley et al. (Scientific Reports, 2022) combining NNMT inhibition with calorie restriction in obese mice. There are no published human clinical trials, and no human pharmacokinetic or efficacy data for 5-Amino-1MQ have been reported. The human-vs-animal gap here is large and should not be glossed over.

The strongest data are preclinical. In cell and rodent models, humanin and HNG reduce neuronal death from amyloid-beta and other insults, shrink infarct size in stroke models, improve glucose handling, and reduce age-related cognitive decline in mice (Yen et al., Scientific Reports 2018; Hashimoto et al., J Neurosci 2001). Human evidence is observational, not interventional: circulating humanin declines with age, is lower in conditions such as Alzheimer's disease and the mitochondrial disorder MELAS, and higher levels have been associated with better "cognitive age" and with longevity-enriched cohorts (long-lived offspring, centenarians). Critically, there are no published randomized controlled trials of exogenous humanin or HNG in humans, and no completed published Phase 1 safety trial, so therapeutic benefit in people remains unproven and the human-versus-animal gap is large.

Documented safety data are limited to short rodent studies, in which investigators reported no overt adverse effects at the doses tested; this is not a substitute for human safety characterization. There are no published human toxicology, drug-interaction, long-term, or reproductive-safety data. Theoretical concerns include the broad and context-dependent roles of NNMT and NAD+/SAM metabolism across tissues (liver, cancer, vasculature), the unknown consequences of chronically altering one-carbon/methylation flux, and the unverified purity and identity of material sold as a "research chemical." Because human safety is essentially uncharacterized, it should be regarded as an experimental compound of unknown human risk.

Because no controlled human trials of administered humanin or HNG have been completed and published, the human safety profile is essentially unknown, including immunogenicity, dosing tolerability, and long-term effects. As a STAT3-activating, anti-apoptotic and growth-signaling peptide, theoretical concerns include effects on cell survival and proliferation pathways, but these have not been characterized clinically. Material sold online as "humanin" is research-use-only chemical of unverified identity and purity, not a pharmaceutical product, adding contamination and mislabeling risks. No safety conclusions for human use can be drawn from the existing animal and cell data.

5-Amino-1MQ is not approved by the FDA (or any major regulator) for any indication and is not a recognized dietary supplement; it is an investigational/research-use-only compound with no publicly documented IND or registered human clinical trials. It is not, as of this writing, a WADA-listed prohibited substance by name, though its NAD+/metabolic mechanism is the kind of area anti-doping bodies monitor.

Humanin and its analog HNG are not approved by the FDA, EMA, or any major regulator for any indication; they are investigational/research-use-only compounds with no completed published Phase 1 human trial. They are not established WADA-prohibited substances by name, but exogenous peptides with growth-factor-like signaling can fall under broad anti-doping categories, so status should not be assumed.